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Abstract
Background: For the patients with node-negative gastric cancer, the 7th edition classification does not define the minimum
number of lymph nodes necessary. We aimed to explore the prognostic significance of examined lymph nodes and
determine how many nodes must be examined.
Methodology/Principal Findings: 435 patients underwent D2 gastrectomy with node-negative gastric cancer between
December 1992 and December 2006 were obtained. Patients were classified into 4 groups by the number of negative LNs
examined during surgery (1-6LNs, 7-10 LNs, 11-15 LNs, and .=16 LNs). Stratified and Cox regression analyses were used to
evaluate the association between survival and the number of negative LNs. Survival was significantly better in the .=16
LNs, compared with the 1-5 LNs, 6-10 LNs and 11-15 LNs group in T2-4 patients; Multivariate analysis demonstrated tumor
size, depth of invasion, 7th UICC stage and the number of examined nodes are strongly independent predictors of survival.
Conclusions: This study first demonstrates that patients with lymph node-negative gastric cancer underwent D2 dissection
should have at least 16 LNs examined, especially in advanced gastric cancer. These results are a reasonable supplement to
our previous tumor-ratio-metastasis staging system and a stratification criterion in clinical pratice.
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Introduction
Gastric cancer is the fourth most common cancer worldwide
[1]. The prognosis of gastric cancer patients remains poor, with
a 5-year overall survival of 25% or less, especially in the USA,
Europe, and China [2,3]. Lymph node metastasis is an important
prognostic indicator for the patients with gastric cancer. It is
widely accepted that a higher survival rate benefits from
a standardized pattern of lymph node dissection [4,5,6]. In
2010, the International Union Against Cancer (UICC) and the
American Joint Committee on Cancer (AJCC) proposed the
seventh edition of the UICC TNM classification with a substantial
change in the staging of gastric cancer. Currently, the new
classification is used most widely for the staging of gastric cancer
[7]. But it does not define the minimum number of lymph nodes
(LNs) necessary, especially for the gastric cancer patients stage
pN0.
Although approximately 15% of the patients with node-negative
disease still go on to die of disease [8], few studies have assessed the
optimal examined number of LNs in patients with lymph node-
negative gastric cancers according to the 7th UICC TNM System.
The aim of the current study was to evaluate the long-term effect
of the number of examined lymph nodes (LNs) on the prognosis of
patients. We further explore the optimal number of LNs for
accurate staging in the patients with node-negative gastric cancer
after D2 dissection.
Materials and Methods
Patient Characteristics
A total of 1551 gastric carcinoma patients undergone D2
gastrectomy at Cancer Center of Sun Yat-sen University between
December 1992 and December 2006 were selected. The eligibility
criteria included histologically confirmed R0 resection, which was
defined as no macroscopic and microscopic residual tumor and
postoperative survival time $6 months. Patients who received
chemotherapy or radiotherapy before surgery and patients with
carcinoma of gastric stump were excluded from the study. D2
lymphadenectomy were performed by experienced surgeons
following the Japanese Research Society for Gastric Cancer
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38681(JRSGC) guidelines [9]. At last, a total of 435 patients were
enrolled in this study. We obtained informed consent from all
participants involved in this study. Ethical approval was obtained
from Sun Yat-sen University Cancer Center research ethics
committee.
The median age of the cohort was 56 years (range, 16–
83 years), and included 293 males and 142 females. All nodal
material was separately dissected from the specimen at the end of
the procedure by the surgeon. Each lymph node was submitted in
separate pots labelled according to their site of origin, then
measured in three dimensions and analyzed by the pathologist.
For all the LNs, one section was routinely examined histopath-
ologically. Sometimes serial sections were also cut from node area
with the aim of the definited diagnosis and staging. Using the best
cut-off approach in terms of the log-rank test, we classified the
patients into four categories: 1-6 LNs, 7-10 LNs, 11-15 LNs and
.=16 LNs.
Follow-up
In general, all patients had follow-up after surgery every
3 months for the first year, every 6 months for the second year,
and twice a year thereafter. The routine examination during
follow-up included a physical examination, blood chemistry, X-
ray of the chest, ultrasound of the liver and abdomen, bone
scan and endoscopy. If the patient had specific symptoms, the
examination was performed as soon as possible for a more
careful assessment. The follow-up period ranged from the first
day of therapy until death or until the last examination visit.
The median follow-up period in our study was 72 months
(range 6–197 months). We used disease-specific mortality for
evaluating the association between the number of negative LNs
and gastric cancer prognosis because it allows for controlling for
unrelated causes of death [10]. The survival time was the time
from diagnosis until the last contact, the date of death, or the
date that the survival information was collected.
Figure 1. Distribution of the number of lymphy nodes
examined for the entire cohort of 435 patients.
doi:10.1371/journal.pone.0038681.g001
Figure 2. Overall survival curves for 4 categories of patients according to the number of the lymph nodes (LNs) examined in 435
patients (P=0.0001).
doi:10.1371/journal.pone.0038681.g002
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Survival analysis and curves were generated from observed
postoperative survival times according to the Kaplan-Meier
method and compared by the log-rank test. Multivariate analyses
were carried out by the Cox proportional hazard model by the
forward stepwise procedure for variable selection. Multivariate P
values were used to characterize the independence of these factors.
The 95% confidence interval (95% CI) was used to quantify the
relationship between survival time and each independent factor.
Differences were considered to be significant at the 5% level. All
analyses were performed by SPSS for Windows, version 18.0
(SPSS, Chicago, IL). Spearman rank correlation coefficient was
used to analyze the relationship between the number of examined
LNs and recurrence rate. The correlation between the number of
examined LNs and post-operative complication rate was analyzed
with logistic regression model. Significance of differences was
assumed at P,0.05.
Results
Patient Characteristics
A total of 435 cases fit the inclusion criteria and were included
in the analysis. According to Martingale residuals of the Cox
model, the cut-off points of the number of examined LNs was
identified as 1–5, 6–10,11–15 and .=16 LNs. Table 1 gives the
characteristics of patients and their tumors according to the
number of examined lymph nodes. Tumor location and depth of
invasion had a significant inuence on the number of examined
lymph nodes. There were no significant differences between the
distribution of gender, age, tumor size or 7th UICC stage and the
4 different categories according to the number of negative LNs.
Number of Examined LNs and Survival
Fig. 1 shows the frequency distribution of examined LNs for the
entire cohort of patients. The mean 6 standard deviation number
of pathologically examined LNs for the entire cohort of
435 patients was 13.564.5, ranging from 1 to 53 (median 12).
As shown in Fig. 2, cancer-specific survival was significantly higher
with an increasing number of negative LNs. The 5-year gastric
cancer-specific survival rate was 65.7% for patients with 1 to 6
negative LNs compared with 70.1%, 79% and 91.2% for those
with 7 to 10, 11 to 15 and more than16 LNs examined,
respectively (P,.001).
Identification of Optimal LN Number
Table 2 shows univariate survival analysis of variables in
patients with node-negative gastric cancer. It revealed that tumor
size, tumor location, depth of invasion, number of examined LNs,
7th UICC stage are associated with gastric cancer-specific survival.
Subgroup analysis was then conducted to evaluate the survival
of the patients in different pathologic T categories. For patients
with T2 tumors, the gastric cancer-specific survival difference was
statistically significant between (,16 vs .=16 negative LNs)
(Fig. 3A). Simiarly, among T3 or T4 cases, patients with .=16
negative LNs had the best disease-specific survival rates (Fig. 3B
and 3C). The gastric cancer-specific survival in the patients with
T1 tumors has no statistically difference. (data not shown).
Survival Analysis
To identify whether the number of negative LNs was associated
with survival, a multivariate logistic regression model was then
applied (Table 3). The results demonstrated that: tumor size, depth
of invasion, 7th UICC stage and the number of examined nodes is
strong independent predictors of survival. Compared to the
patients who had fewer than 6 examined nodes, patients with 6–
10,11–15 and .=16 LNs examined had a significantly lower
chance of death during their gastrectomy.
Discussion
Previously, we found that positive lymph node ratio (LNR) is an
independent prognostic factor in gastric cancer after D2 resection
regardless of the number of retrieved lymph nodes [11].
Furthermore, we demonstrated tumor-ratio-metastasis (TRM)
staging system is an alternative to the 7th edition UICC TNM
system in gastric cancer after D2 resection [12]. These results
make it possible that a staging system based on the TRM could
substitute for the current UICC classification, especially when the
examined number of lymph nodes is not enough. However, it is
difficult to evaluate the prognosis of patients by TRM for lymph
node-negative gastric cancer [13].
In present study, all the node-negative gastric cancer patients
underwent D2 resection, which is widely performed as a standard
surgical procedure for gastric cancer in Asian countries. In order
to assess the effect of the number of negative LNs on gastric cancer
prognosis, disease-specific survival is used in our analyses to
control for unrelated causes of death. The findings showed that the
patients have a better disease-specific survival rate with increasing
Table 1. Distribution of clinicopathologic characteristics for
four categories by the number of examined lymph nodes.
Vatible No. of examined nodes (n) P
126 7–10 11–15 .=16
Gender 0.191
Male 75(17.2%) 56(12.95) 72(16.6%) 90(20.7%)
Female 30(6.9%) 21(4.8%) 33(7.6%) 58(13.3%)
Age (years) 0.053
#60 56(12.8%) 41(9.4%) 69(15.9%) 99(22.8%)
.60 49(11.3%) 36(8.3%) 36(8.3%) 49(11.3%)
Tumor size (cm) 0.167
#5 66(15.2%) 50(11.5%) 66(15.2%) 106(24.4%)
.5 39(9%) 27(6.2%) 39(9%) 42(9.7%)
Tumor location 0.000
Lower 30(6.9%) 29(6.7%) 45(10.3%) 93(21.4%)
Upper 67(15.4%) 38(8.7%) 41(9.4%) 34(7.8%)
Middle 6(1.4%) 7(1.6%) 18(4.1%) 19(4.4%)
Diffuse 2(0.5%) 3(0.7%) 1(0.2%) 2(0.5%)
Depth of invasion 0.032
T1 17(3.9%) 12(2.8%) 24(5.5%) 44(10.1%)
T2 19(4.4%) 17(3.9%) 17(3.9%) 26(6%)
T3 18(4.1%) 15(3.4%) 24(5.5%) 38(8.7%)
T4 51(11.7%) 33(7.6%) 40(9.2%) 40(9.2%)
7th UICC stage 0.082
IA 17(3.9%) 12(2.8%) 24(5.5%0 44(10.1%)
IB 19(4.4%) 17(3.9%) 17(3.9%) 26(6%)
IIA 18(4.1%) 15(3.4%) 24(5.5%) 38(8.7%)
IIB 48(11%) 31(7.1%) 38(8.7%) 36(8.3%)
IIIB 3(0.7%) 2(0.5%) 2(0.5%) 4(0.9%)
doi:10.1371/journal.pone.0038681.t001
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reasons for that. First, some patients pathologically negative nodes
in fact may have had cancer disseminated to regional LNs.
Although all the patients underwent D2 dissection, the pathologists
and surgeons vary in efforts and techniques in searching for lymph
nodes, which could lead to omitted nodes in the specimen [14,15].
As the number of LNs examined increases, the probability of
missing a positive LN decreases and so does the proportion of
patients with higher-stage disease who are misclassified as lower-
stage. A low LNs examined results in an underestimation of stage,
which is known as the Will Rogers phenomenon [10,16]. Second,
the contribution of negative node number to the prognosis of
patients is partly due to considerably high rate LN micrometas-
tases [17]. In node-negative patients identified by routine
histologic examination, about 17%–32% had LN micrometastases
[18,19]. The patients with micrometastases often have an
especially high risk for recurrence [20].
In current study, our data remarked depth of invasion and the
number of examined nodes is strong independent predictors of
survival in multivariate logistic regression model, which is similar to
otherstudies[8,20].Moreover,thenumberofexaminedlymphnodes
isassociatedwithdepthofinvasion(Tstage).Therefore,weanalyzed
thesurvivaldifferencesbetweengroupsaccordingtodifferentTstage.
Compared to the patients who had fewer than 6 examined nodes,
patients with 6–10,11–15 and .=16 LNs removed had a signifi-
cantly lower chance of death in patients with T2–4 disease. These
patientsarealsodefinedasadvancedgastriccancer,whichconstitutes
the majority of gastric patients inclinical practice[21].
As for T1 stage gastric cancers in present study, the number of
T1 cases is small and the 5-year survival rate is up to 97%, thus the
gastric cancer-specific survival among them has no statistically
difference. Additionally, the alternative explanation for this may
be that patients with T1 classification seldom spread to regional
LNs. The incidence of node metastasis in T1 patients about is only
15%–20% [22,23]. However, it is difficult to determine depth of
invasion and lymph node metastasis before surgery. Therefore, our
data strongly suggest that at least 16 LNs should be removed
during D2 resection.
Figure 3. Gastric cancer-specific survival was found to be significantly higher among patients with .16 negative LNs compared
with those with ,16 LNs. (A) Gastric cancer-specific survival curves in pathological T2 patients according to the number of negative lymph nodes
(LNs) (P=0.040). (B) Gastric cancer-specific survival curves in pathological T3 patients according to the number of negative lymph nodes (LNs)
(P=0.007). (C) Gastric cancer-specific survival curves in pathological T4 patients according to the number of negative lymph nodes. (P,0.001).
doi:10.1371/journal.pone.0038681.g003
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lymph node number in lymph node-negative gastric cancer
patients. Bouvier showed that at least 10 lymph nodes must be
examined in order to accurately stage gastric carcinoma in node-
negative cancers [24]. However, in their studies, most patients
consisted underwent D1 resection, different from the current
patients with only D2 resection. In the past, as some trials failed to
demonstrate a survival benefit of D2 over D1 dissection, D1
lymphadendctomy resection was always performed in the Western
countries [25,26]. Whereas oriental surgeons do not accept the
results and routinely perform D2 gastrectomy [27]. In fact, with
the release of the latest clinical trial results, D2 lymphadenectomy
is gradually becoming the recommended surgical approach for
patients with resectable gastric cancer [28]. Baiocchi et al. also
assessed 301 lymph node-negative gastric carcinoma patients with
D2 resection [20]. They identified retrieval of more than 25 nodes
may be warranted. Compared with our results, their selected were
the patients with more than 15 nodes pathologically analyzed.
However, many population-based studies of gastric cancer have
found that surgeons and pathologists failed to accomplish more
than 15 nodes [29,30,31]. Therefore, it is very important and
meaningful to evaluate prognostic value less than 15 nodes of in
lymph node-negative gastric cancer.
In addition, none of the above studies described the method of
selecting of the reported cut-offs among the above studies. In this
study, we examined the functional form of the covariate under
study by Martingale residual analysis and identified the cutoff
points of the number of examined LNs as 1-6 LNs, 7-10 LNs, 11-
15 LNs, and .=16 LNs [32,33]. We believe the method can
discriminate the survival differences between groups and make our
study objectively valid [34,35,36].
In conclusion, the current study first demonstrates that patients
with lymph node-negative gastric cancer following D2 dissection
should have at least 16 LNs examined, especially in advanced
gastric cancer. It should be used as a reasonable supplement to our
TRM staging system and a stratification criterion in clinical
pratice according to the 7th Edition UICC TNM System.
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Table 2. Univariate analysis of variables in patients with
node-negative gastric cancer.
Characteristics 5-year survival rate (%) P
Gender 0.288
Male 76.5
Female 82.4
Age (years) 0.067
#60 81.5
.60 73.5
Tumor size (cm) 0.000
#5 89.2
.5 57.1
Tumor location 0.000
Lower 85.3
Upper 73.9
Middle 76
Diffuse 25
Depth of invasion 0.000
T1 97.9
T2 83.5
T3 77.9
T4 64.6
Number of examined LNs 0.000
1–6 65.7
7–10 70.1
11–15 79
.=16 91.2
AJCC stage 7th 0.000
IA 97.9
IB 83.5
IIA 77.9
IIB 66.7
IIIB 36.4
doi:10.1371/journal.pone.0038681.t002
Table 3. Independent prognosic factor for cancer-specific
survival by multivariate Cox regression analysis for the entire
cohort of patients (n=435).
Prognosic
variable
Relative
risk 95%CI for HR P
Lower upper
Tumor size (cm) 0.000
#51
.5 0.287 0.181 0.455
Tumor location 0.931
Lower 1
Upper 0.895 0.354 2.26
Middle 0.952 0.344 2.639
Diffuse 0.917 0.36 2.333
Depth of invasion 0.000
T1 1
T2 0.09 0.021 0.378
T3 0.625 0.332 0.179
T4 0.838 0.499 1.408
Number of examined
LNs
0.000
1–6 1
7–10 4.262 2.182 8.322
11–15 2.568 1.256 5.25
.=16 1.965 0.977 3.955
AJCC stage 7th 0.000
IA 1
IB 0.023 0.005 0.114
IIA 0.193 0.075 0.508
IIB 0.269 0.109 0.668
IIIB 0.455 0.195 1.061
doi:10.1371/journal.pone.0038681.t003
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